Akeso's experimental drug helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' Tevimbra in a study presented Sunday. The treatment also cut the risk of death by more than one-third, a positive development for Akeso and a potentially competitive setback for BeOne in lung cancer immunotherapy. The news is clinically meaningful but likely company-specific rather than broad market-moving.
Akeso's experimental drug helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' Tevimbra in a study presented Sunday. The treatment also cut the risk of death by more than one-third, a positive development for Akeso and a potentially competitive setback for BeOne in lung cancer immunotherapy. The news is clinically meaningful but likely company-specific rather than broad market-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
